Protagonist’s $50M milestone; Swiss biotech raises $27M; Kymera halts a PhI

Plus, news from CEPI and ProJenX:

Protagonist Therapeutics records a $50M milestone: The company said Wednesday that it’s getting a $50 million milestone from its agreement with Johnson & Johnson. The milestone was triggered by the third patient being dosed in a Phase III trial evaluating a psoriasis treatment. Protagonist said it expects to launch additional Phase III studies for the oral peptide next year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Take Command Secures $25M to Expand ICHRAs Coverage

What You Should Know: – Take Command, a Dallas-based SaaS platform and employer-sponsored, personalized health benefits space secures $25M in growth stage financing led by

September 21, 2023

Bright Green Embarks on Major Partnership With Benuvia Pharmaceuticals Will Supply Pharma Expert With American Made Raw Materials From Its Industry Leading and DEA-Approved SCH I & II Drug Facility | Psychedelic Invest

GRANTS, NEW MEXICO, Aug. 21, 2024 (GLOBE NEWSWIRE) — Bright Green Corporation (Nasdaq: BGXX) (“Bright Green” or the “Company”) today announced that it has signed a letter of intent

August 22, 2024

SmarterDx Nabs $50M for AI-Powered Revenue Integrity for Hospitals

What You Should Know: – SmarterDx, the leader in clinical AI for revenue integrity and care quality, today announced it has secured $50 million in

May 14, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.